






THE FRITSMA FACTOR Your	Years of Poter Befo	ntial Life Lo ore Age 65	· /
Interactive Hemostasis	Cause of Death	YP	LL
	Percent		
	All Causes	948,426	100.0%
	Unintentional Injury	199,903	21.1%
	Suicide	52,265	5.5% 31.7%
	Homicide	48,190	5.1%
	Malignant Neoplasms	137,221	14.5%
	Heart Disease	107,009	11.3%
	Perinatal Period	75,496	8.0%
	Congenital Anomalies	43,615	4.6%
E Istanetate	Cerebrovascular	21,817	2.3%
erling becauty	HIV	21,508	2.3%
	Liver Disease	21,352	2.3%
Brits	All Others	220,050	23.2%
	Prevention and Cont	rol. Web-based Injury S	National Center for Injury tatistics Query and Reporting w.cdc.gov/injury/wisqars











































THE FRITSMA	Injury Severity Score (ISS)					
FACTOR Your Interactive Hemostasis	Region	Description (Examples)	Injury Score (1−6)	Highest 3 Squared		
Resource	Head & neck	Cerebral contusion	3 (Serious)	9		
	Face	Scratches	1 (Minor)			
	Chest	Sucking wound	4 (Severe)	16		
	Abdomen	Liver contusion Spleen rupture	2 (Moderate) 5 (Critical)	25		
	Extremity	Fractured femur	3 (Serious)			
	External		1 (Minor)	1		
	Sum		ISS:	50		
	Maximum is 75. If injury is assigned a score of 6 (unsurvivable), the ISS is automatically 75. ISS correlates linearly with mortality, morbidity and hospital stay. See also automated revised ISS, TRISS, which incorporates respiration and BP.					
Med T		ne injury severity score: a nd evaluating emergency o				
	The Fritsma Factor			Coagulopathy		


THE FRITSMA FACTOR Your Interactive	Probability of Life-threatening Coagulopathy in Trauma				
Interactive Hemostasis Resource	n = 58, received >10 RBCs Condition:	% Coagulo- pathy*			
	Injury severity score (ISS) >25 alone	10%			
	ISS >25 & systolic BP <70 mm Hg	39%			
	ISS >25 & body temp <34°C	49%			
	ISS >25 & pH <7.10	58%			
	ISS >25; SBP <70 mm Hg; body temp <34°C	85%			
	ISS >25; SBP <70 mm Hg; temp <34°C; pH <7.10	98%			
	*Life-threatening coagulopathy is arbitrarily defined as >2X mean of reference interval (MRI)	PT and PTT			
	Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulop transfused trauma patient: hypothermia and acidosis revisited. J Trauma 1 The Fittuma Factor				


THE FRITSMA FACTOR	Coagulopathy in Trauma				
Interactive Hemostasis Resource	ISS & Coagulopathy n = 1088	% Coagulopathy by Lab Assay*			
	ISS >15; median 20	57.7%			
	ISS <15	10.9%			
	Coagulopathy at Admission	% Mortality			
	Yes (24.4%)	46%			
	No	10.9%			
	Overall mortality	19.5%			
Description	*Coagulopathy defined independent of PT >18s, 16.3%; PTT >60s, 24.4%; or three				
	Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54: 1127–30				
	The Fritsma Factor	Coagulopathy 23			





















tive stasis	Independent Outcome	RBCs	No RBCs			
	Sepsis	16.4%	9.8%			
	Pulmonary complication	12.6%	6.0%			
	Wound complications	9.2%	4.7%			
	Mortality	6.4%	4.4%			
	Thromboembolic disease	4.0%	1.9%			
	Renal complications	2.7%	1.9%			
	Cardiac complications	2.1%	1.4%			
isteratory	30-day outcomes, all significant at p < 0.05					






FRITSMA FACTOR	RBC Risks and Indications					
our Iteractive emostasis	Risk	Indication				
tesource	ABO Incompatibility*	fever, hemoglobinuria, hemoglobinemia				
	TRALI* or TACO	respiratory distress, hypoxemia				
	Bacterial contamination	fever, hypotension				
	Allergic reaction	Urticaria				
	Citrate toxicity	Hypocalcemia				
1.41	Terminate transfusion an	d start diagnostic tests				
teren er bestramentation	*Observe for delayed TR	ALI and transfusion reaction				
2						
S AND	The Fritsma Factor					





mostasis source	Preparation	Factor V	Factor VIII	Protein S
	FFP at thaw	85%	81%	97%
	FFP 5d post-thaw	67%	43%	92%
	PF24 at thaw	86%	66%	90%
	PF24 5d post-thaw	59%	48%	78%
	PF24RT24 at thaw	90%	86%	82%
	PF24RT24 5d post-thaw	89%	86%	73%







ASA Plasma Indications


Manage preoperative or bleeding pts who require replacement of multiple coagulation factors (eg, liver disease, DIC).


- Manage patients undergoing massive transfusion who have clinically significant coagulation deficiencies.
- Manage bleeding patients taking warfarin or who need an invasive procedure before vitamin K could reverse the warfarin effect (but 4-factor PCC is better).
- Transfusion or plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)
- Manage patients with congenital or acquired factor deficiencies for which there are no specific coagulation concentrates

- FP24T24 not indicated for factor VIII or protein S deficiency:
Practice guidelines for perioperative blood transfusion and adjuvant therapies: an
updated report by the American Society of Anesthesiologists Task Force on Perioperative
Blood Transfusion and Adjuvant Therapies. Anesthesiology 2015;22:241–75.
Plasma 39














THE FRITSMA FACTOR		Ρ	lasma	Effic	а	icy ir	n Adult	S
Your Interactive Hemostasis Resource		INR	Median FFP n=2543	Median Change		PTT	Median FFP n=2543	Median Change
		All	11.4 mg/kg	-0.2	1	All	11.4 mg/kg	-2.6 s
		≤1.5	10.9 mg/kg	0.0	1	<30 s	11.0 mg/kg	+2.8 s
		1.6–1.7	10.9 mg/kg	-0.2		30–39 s	10.8 mg/kg	–1.3 s
		1.8–1.9	12.1 mg/kg	-0.3		40–49 s	11.7 mg/kg	-5.8 s
		2.0-2.1	11.4 mg/kg	-0.4		≥50 s	12.6 mg/kg	–19 s
		2.2–2.5	11.6 mg/kg	-0.6	1	• "The m	edian reductions	s in INR
		2.6–2.9	12.3 mg/kg	-0.9]		eater when the	pre-plasma
		3.0-4.9	11.5 mg/kg	-1.8]		s were higher." edian reduction	in DTT was
		≥5.0	10.5 mg/kg	-2.0	1		when the pre-pl	
R.	Sta	anworth SJ,		owe D, et al	I. 1	0		
COX61		e Fritsma Factor		in addito an	u.	ormaren. rra	101001011 2011, 01	Plasma 4
















THE FRITSMA FACTOR	Tranexamic Acid Death by Cause							
Interactive Hemostasis	CRASH-2	TXA	Placebo	RR	р			
Resource		n = 10060	n = 10067					
	Any cause of death	1463 (14.5%)	1613 (16%)	0.91	0.0035			
	Bleeding death	489 (4.9%)	574 (5.7%)	0.85	0.0077			
	Thrombosis death	33 (0.3%)	48 (0.5%)	0.69	0.096			
	No significant differen blood products	ces in myocar	dial infarct,	stroke	, VTE,			
Elever	Shakur H, Roberts I, Bautista occlusive events, and blood tr (CRASH-2): a randomized, pla	ansfusion in traum	a patients with s	significa	nt hemorrha	ge		
A MARCH	The Fritsma Factor				TXA	5		

